Evidence map›Paper›PMID 36816726›Full record

ArticleFrontiers in medicine2022

Low prevalence of hepatitis delta infection in Cuban HBsAg carriers: Prospect for elimination.

Licel de Los Ángeles Rodríguez Lay, Zexi Tan, Maria Caridad Montalvo Villalba, Marcia Samada Suárez, Marité Bello Corredor, Dayesi López Hernández, Barbara Marrero Sánchez, Lidunka Valdés Alonso, Aurélie Sausy, Judith M Hübschen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Licel de Los Ángeles Rodríguez LayNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Zexi TanNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Maria Caridad Montalvo VillalbaNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Marcia Samada SuárezCentro de Investigaciones Médico Quirúrgicas, Havana, Cuba.
Marité Bello CorredorNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Dayesi López HernándezNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Barbara Marrero SánchezNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Lidunka Valdés AlonsoNational Reference Laboratory of Viral Hepatitis, Department of Virology, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba.
Aurélie SausyClinical and Applied Virology Group, Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.
Judith M HübschenClinical and Applied Virology Group, Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.
Instituto de Medicina Tropical “Pedro Kourí” · CULuxembourg Institute of Health · LUUniversidad de Ciencias Médicas de la Habana · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Infection with hepatitis delta virus (HDV) is one of the most severe hepatitis B virus (HBV) complications, with a more rapid progression to cirrhosis and an increased risk of hepatic decompensation and death. Data on HDV infection in Cuba are limited. The aims of our study were to determine the HDV prevalence in HBsAg carriers and to characterize the HDV strains circulating. The data were used to assess the possibility of HDV elimination in the Cuban HBV epidemiological setting. Methods: Five hundred and two serum samples from the same number of HBsAg carriers collected in the period 2006-2019 from all over the country were tested for anti-HDV total antibodies. If positive, the samples were analyzed for HDV-RNA using Real-Time RT-PCR targeting the ribozyme and HD antigen domains followed by genotyping based on phylogenetic analysis. Results: Two samples were anti-HDV positive [0.39% (95% CI 0.11-1.44)]. One of them was also HDV-RNA positive. Clinically, the patient with active HDV infection had compensated liver cirrhosis. Phylogenetic analysis showed that the virus belonged to genotype 1 and thus clustered with contemporary strains from North America, Europe, Middle East, and Asia. Discussion: This is the first HDV study, including molecular detection and virus characterization, done after the introduction of the universal childhood anti-hepatitis B vaccination. The very low prevalence of HDV infection in HBsAg carriers combined with the high HBV vaccination coverage of all newborn children, of previously identified risk groups, and of the general population currently under 40 years of age suggests that HDV elimination is feasible in Cuba if the success in HBV control is maintained.

Indexed as

HBsAg carriersHDV eliminationhepatitis B vaccinationhepatitis B virushepatitis delta virus (HDV)

Identifiers

PMID36816726
PMCPMC9928864
OpenAlexW4318820721

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.